ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • Exercise Training on Health Outcomes in Scleroderma (ETHOS) Trial

    Current treatment strategies for SSc are targeted towards inflammation and pain relief, however they have a modest impact on addressing exertional intolerance, functional disability and their underlying physiology. On the other hand, there is a lack of defined evidence into other preventative non-pharmacological therapeutics such as exercise training in the clinical management of SSc. Due to its multifactorial effects on organ systems, exercise training has been proposed as an ideal adjunct strategy to address functional impairment, symptomatology and/or organ involvement in patients with SSc. However, the efficacy of exercise training in patients with SSc has primarily been explored in small pilot studies with safety-related or patient-reported endpoints. The impact of exercise to alter the physiologic factors that are contributing to symptom burden and morbidity in SSc has not received sufficient attention. Consequently, we want to evaluate whether a goal-directed exercise approach could be efficacious in addressing functional disability.

  • Phase 1 Safety and Pharmacology Study of Oral GBP-088 in Healthy Adults

    This project is testing the safety and pharmacokinetics of a single oral dose of a new drug called GBP-088 when given with and without food. GBP-088 is being developed for the treatment of recurrent kidney stones. You may be eligible for this study if you are a healthy adult man or woman aged between 18 and 55 years old. You will receive a single oral dose of active study drug on Day 1 under fasted conditions. After a 4 day washout period you will receive the same oral dose of active study drug given after eating a high fat, high calorie meal. It is hoped that this research will help determine the safety of GBP-088 when given to healthy men or women so that it can be tested in patients with recurrent kidney stone disease

  • Evaluating a wearable Ambulatory Electrocardiogram (AECG) device for monitoring people with suspected abnormal heart rhythms

    The study aims to evaluate the performance of the Lubdub AECG device compared with a clinically accepted AECG device used in routine clinical care. Participants who are already referred for AECG monitoring will wear both devices at the same time for 24 to 48 hours. The study will assess the technological performance of the Lubdub AECG device during normal daily activities compared to the comparator AECG device. We expect to evaluate if the Lubdub AECG device will provide ECG recordings, signal quality and technological performance comparable to the clinically accepted AECG device, while maintaining high levels of participant usability and comfort.

  • Intranasal naloxone for the reversal of opioid overdose

    Opioid overdose is a major public health issue, causing significant morbidity and mortality. Naloxone is a drug for reversal of opioid overdose and is typically administered through intravenous or intramuscular injection. Intranasal administration of naloxone has several advantages over injection, particularly ease of use and removal of the risk of needle stick injury. This study is a randomised controlled trial to test the hypothesis that naloxone administered intranasally will be non-inferior to naloxone administered intramuscularly in achieving an adequate response (no requirement for a rescue dose of intramuscular naloxone). There is limited quality evidence about intranasal naloxone efficacy. Previous trials used volumes greater than the now-recommended optimal delivery volume for intranasal drug administration, of equal to 0.2ml per nostril, or smaller doses than those typically used in the Australian context. Our trial will evaluate the efficacy of a concentrated naloxone spray (2mg/0.1ml) compared to the 800mcg intramuscular standard in reversing the effects of opioid overdose and the production of any naloxone-associated side-effects.

  • Focal therapy using the Pro-Focal laser system for men with prostate cancer recurrence after previous radiotherapy

  • Virtual reality-based gradual exposure program for persistent dizziness after brain injury: a feasibility and acceptability study

    Dizziness is one of the most common and disabling symptoms after an acquired brain injury (ABI), such as concussion or traumatic brain injury. Many people begin to avoid movements, places and activities that bring on their dizziness, which can slow recovery, increase the risk of falls, and affect mood, work and quality of life. Standard vestibular (balance) rehabilitation gradually exposes people to movements and environments that provoke symptoms, but is usually delivered using simple 2D videos that lack real-world realism. This study will recruit participants to take part in a virtual reality (VR) program delivered by trained clinicians during their usual outpatient rehabilitation sessions at the Brain Injury Rehabilitation Service (BIRS) Day Hospital or Concussion Clinic at the Princess Alexandra Hospital. Participants will wear a VR headset and be gradually exposed to virtual environments that vary in visual busyness and movement, chosen and progressed by their treating clinician based on their individual symptoms and goals. The sessions will last for about 30 minutes. Questionnaires and balance assessments will be completed before and after the program, and some participants and clinicians will be invited to a short interview about their experience. It is hoped this study will show that VR-based graded exposure is practical, safe and acceptable in outpatient brain injury rehabilitation. The study will also be used to provide early evidence about its effects on dizziness, avoidance of activity, anxiety and everyday function. The findings will inform a future larger controlled trial.

  • Evaluation of Nasal Biomarkers for Objective Assessment of disease severity in Respiratory Disorders – Extended for Multiple Sites

    This research study is an observational, single site study quantifying expression of biomarkers of respiratory disease in nasal fluid using the ABEL microsampler device. The primary objective of this study is to compare biomarker expression between healthy controls and participants with respiratory disorders such as chronic obstructive pulmonary disorder (COPD), hayfever, chronic sinusitis, asthma and rhinitis.

  • Matrix Matters: The Role of Intrinsic Beef Fat in Modulating Postprandial Muscle Protein Synthesis in Humans

    Our proposed study will address this gap by comparing postprandial muscle protein synthesis in response to iso-nitrogenous beef meals varying in fat content and structure: lean steak, higher-fat steak, and lean steak with added rendered tallow. We will assess this in the rested state, which better reflects typical feeding patterns and avoids confounding from exercise-enhanced responses.

  • Can Adding Mindfulness Training to a Voice Care Programme Improve Vocal Fatigue and Voice Health in University Teaching Staff? A Pilot Randomised Controlled Trial

    University teaching staff are at increased risk of vocal fatigue and voice disorders due to high occupational voice demands. This pilot randomised controlled trial will evaluate the feasibility, acceptability, and preliminary effectiveness of supplementing a standard Voice Care Programme with a mindfulness-based intervention. Sixty University of Melbourne teaching staff with vocal fatigue will be randomly allocated to either a Voice Care Programme alone or a Voice Care Programme plus mindfulness intervention. Feasibility outcomes will include recruitment, retention, adherence, and participant acceptability. Preliminary effectiveness outcomes will include vocal fatigue, voice quality, phonation threshold pressure, psychological distress, interoceptive awareness, and burnout.

  • Consumer expeRiencE of suPpLemEnt on agiNg sIgns and Skin Hydration

    This study uses a double-blind, placebo-controlled, randomized, parallel group study design. This study involves the testing for eight weeks of a TGA-listed off-shelf supplement (Swisse Nutra Cellular Skin Hydration product), The research study aims to compare the effect of the product against a placebo on objective measures of skin hydration, wrinkle reduction, water loss and skin elasticity, as well as change of the measures from first visit. It also aims to compare the end user experience of the product against a placebo in an eight-week real-life product testing.

Tags:
  • Finding clinical trials